Literature DB >> 33047193

Primary meningeal osteoblastic osteosarcoma containing fibroblast osteosarcoma: clinicopathological analysis and literature review.

Y Q Qiu1, Y L Chen2.   

Abstract

Primary meningeal osteosarcoma is rare. The aim of this report is to investigate the symptoms, imaging data, pathological diagnosis, and treatment of primary meningeal osteosarcoma. A 54-year-old male patient was admitted to hospital because of numbness and weakness in the right limb, accompanied by dizziness and chest tightness. The CT and MRI examination of the patient showed multiple irregular mixed density mass signal shadows. After preliminary examinations and tests, meningioma was considered. After surgical resection, the mass was sent for pathological examination, and primary meningeal osteosarcoma was finally diagnosed. The patient did not receive radiotherapy and chemotherapy and died 7 months later. Primary meningeal osteosarcoma is a rare and easily misdiagnosed disease. There is no test that is specific enough up to now, so the correct diagnosis can only be determined by a histopathological examination. At present, there are no clear drug, radiotherapy, and chemotherapy guidelines for the treatment of this disease in addition to surgery, and the prognosis is poor.

Entities:  

Keywords:  Clinicopathological analysis; Fibroblast osteosarcoma; Primary meningeal osteosarcoma

Year:  2020        PMID: 33047193     DOI: 10.1007/s00198-020-05675-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  1 in total

1.  Neuroradiologic features of primary falx osteosarcoma.

Authors:  A M Wang; T J Fitzgerald; A H Lichtman; T C Power; A A Zamani; H A Haykal; C L Rumbaugh
Journal:  AJNR Am J Neuroradiol       Date:  1986 Jul-Aug       Impact factor: 3.825

  1 in total
  1 in total

1.  MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma.

Authors:  Hongyu Lian; Yang Zhou; Zhang Sun; Kexin Liu
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.